rss
Ann Rheum Dis 2003;62:316-321 doi:10.1136/ard.62.4.316
  • Extended report

Number needed to treat (NNT): implication in rheumatology clinical practice

  1. M Osiri1,
  2. M E Suarez-Almazor2,
  3. G A Wells3,
  4. V Robinson4,
  5. P Tugwell4
  1. 1M Osiri, Department of Medicine, Chulalongkorn University Hospital, Bangkok, Thailand
  2. 2M E Suarez-Almazor, Health Services Research, Baylor College of Medicine, Veteran Affairs Medical Center, Houston, Texas, USA
  3. 3G A Wells, Faculty of Epidemiology and Community Medicine, University of Ottawa, Ontario, Canada
  4. 4V Robinson, P Tugwell, Center for Global Health, Institute of Population Health, University of Ottawa, Ottawa, Ontario, Canada
  1. Correspondence to:
    Dr P Tugwell, Center for Global Health, University of Ottawa, Institute of Population Health, 1 Stewart Street, Room 312, Ottawa, Ontario, Canada, K1N 6N5;
    elacasse{at}uottawa.ca
  • Accepted 2 September 2002

Abstract

Objective: To calculate the number needed to treat (NNT) and number needed to harm (NNH) from the data in rheumatology clinical trials and systematic reviews.

Methods: The NNTs for the clinically important outcome measures in the rheumatology systematic reviews from the Cochrane Library, issue 2, 2000 and in the original randomised, double blind, controlled trials were calculated. The measure used for calculating the NNT in rheumatoid arthritis (RA) interventions was the American College of Rheumatology 20% improvement or Paulus criteria; in osteoarthritis (OA) interventions, the improvement of pain; and in systemic sclerosis (SSc) interventions, the improvement of Raynaud's phenomenon. The NNH was calculated from the rate of withdrawals due to adverse events from the treatment.

Results: The data required for the calculation of the NNT were available in 15 systematic reviews and 11 original articles. For RA interventions, etanercept treatment for six months had the smallest NNT (1.6; 95% confidence interval (CI) 1.4 to 2.0), whereas leflunomide had the largest NNH (9.6; 95% CI 6.8 to 16.7). For OA treatment options, only etodolac and tenoxicam produced significant pain relief compared with placebo (NNT=4.4; 95% CI 2.4 to 24.4 and 3.8; 95% CI 2.5 to 7.3, respectively). For SSc interventions, none were shown to be efficacious in improving Raynaud's phenomenon because the 95% CI of the NNT was infinite.

Conclusions: The NNT and NNH are helpful for clinicians, enabling them to translate the results from clinical trials and systematic reviews to use in routine clinical practice. Both NNT and NNH should be accompanied by a limited 95% CI and adjusted for the individual subject's baseline risk.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Responses

    1. Submit a response
    2. No responses published

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.